Aside from toxicity and maintenance of supraphysiological levels of estrogens, a direct comparison between different classes of anti-estrogens – such as aromatase inhibitors and estrogen receptor inhibitors – is not feasible unless the cancer cells have been modified to overexpress aromatase (Jelovac et al., 2004). The gene discussed is CYP19A1; the disease is cancer.